Navigation Links
Transposagen Issued Two Key U.S. Patents

LEXINGTON, Ky., Nov. 1, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today the issuing of Patent No. 8,399,643 entitled, "Nucleic Acids Encoding Hyperactive PiggyBac Transposases" on March 19th and Patent No. 8,558,055 entitled, "A Genetically Modified Rat Comprising a Cytokine Gene Disruption and Exhibiting a Greater Susceptibility to a Cytokine-Mediated Autoimmune and/or Inflammatory Disease" on October 15th. The patents have terms extending through 2030.


The piggyBacTM DNA transposon is the most efficient and safe technology for delivering DNA stably into the genome of animals and is being used in biomedical, agricultural and human therapeutic applications. Transposagen tested over 2 million variations of the piggyBacTM transposase enzyme and discovered versions of the enzyme that are more than 10 times more active than the version found in nature. The piggyBacTM technology is also a critical component of Footprint-FreeTM Gene Editing, one of the only commercially available methods to edit as little as a single nucleotide in the genome of nearly any organism. "The new 'super piggyBacTM vectors and PB-GoldTM kit, will allow researchers to perform stable transfection for the same cost and on the same timeline as transient transfection." said Jack Crawford, M.Sc., Transposagen's Director of Sales and Marketing.

The more recent patent covers all genetically modified rats that model lymphocyte proliferation, autoimmune disease or inflammatory disease, including all genetically modified rats with dysfunction in macrophages, immunoglobulin, T-cells, B-cells and/or NK-cells. The patent further covers any assay that screens for potentially useful therapeutic compounds using cells derived from the genetically modified rats. "This patent, and other imminent patents that cover genetically modified rat models of cancer and other diseases, cements Transposagen's position as a premier provider of custom genetically modified rodents," said Eric Ostertag, M.D., Ph.D., President & CEO of Transposagen. "We are proud to be the sole provider of valuable research reagents, such as the hyperactive piggyBacTM transposase and rat models of inflammatory disease, to the research community."

Please see piggyBacTM for more information, as well as Disease Model Partnering Strategy for opportunities in rodent model creation.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen specializes in gene editing tools and custom cell line and animal model creation. To learn more, please visit:

Media Contact: Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115,

News distributed by PR Newswire iReach:

SOURCE Transposagen Biopharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Transposagen Receives Over $4.3M in Grants and Investment
2. Enbrel® (etanercept) Patent Issued
3. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
4. 12th U.S. Patent Issued To Dyadic International
5. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
6. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
7. Stemedica Issued U.S. Patent For Ectodermal Stem Cells
8. PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
9. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
10. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
(Date:10/13/2015)... NEW YORK , October 13, 2015 ... biotechnology acceleration and development company, has entered into a ... New York and Paris, France ... --> --> This collaborative ... a highly respected scientific advisory team as well as ...
(Date:10/13/2015)... TORONTO , Oct. 13, 2015  Generex Biotechnology ... has entered into a non-binding Letter of Intent (LOI) with ... that has developed a proprietary cooling technology designed to improve ... the United States and three million ... of 25 and 44 diagnosed as infertile.  For 42% of ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from ... in the U.S. for the ablation of prostate tissue. Sonablate® is the first ...
(Date:10/13/2015)... 13, 2015 the United States ... .  PRCC represents about 14% of all new cases of kidney ... Canada and Europe . ...   --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) ... and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in a global ...
Breaking Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):